Atara Biotherapeutics Q1 2024 Earnings Report $5.59 -0.33 (-5.57%) As of 04/4/2025 04:00 PM Eastern Earnings HistoryForecast Atara Biotherapeutics EPS ResultsActual EPS-$5.75Consensus EPS -$9.25Beat/MissBeat by +$3.50One Year Ago EPSN/AAtara Biotherapeutics Revenue ResultsActual Revenue$27.36 millionExpected Revenue$27.00 millionBeat/MissBeat by +$360.00 thousandYoY Revenue GrowthN/AAtara Biotherapeutics Announcement DetailsQuarterQ1 2024Date5/9/2024TimeN/AConference Call ResourcesSlide DeckPress ReleaseATRA Earnings HistorySlide DeckFull Screen Slide DeckPowered by Remove Ads Atara Biotherapeutics Earnings HeadlinesGenocea Biosciences (NASDAQ:GNCAQ) vs. Atara Biotherapeutics (NASDAQ:ATRA) Head-To-Head ContrastMarch 30, 2025 | americanbankingnews.comAtara Biotherapeutics (ATRA) Receives a Buy from TD CowenMarch 10, 2025 | markets.businessinsider.comWill the U.S. military protect this $10B gold mine?You don’t need the gold price to move another inch for this company to potentially re-rate several hundred percent higher. All it takes is the market realizing the U.S. military has the DRC’s back - and that moment may be days away. The last time political risk collapsed on a project like this, early investors saw once-in-a-decade gains.April 6, 2025 | Golden Portfolio (Ad)Atara Biotherapeutics Faces Potential Liquidation: Strategic Decisions Crucial for Investor OutcomesMarch 9, 2025 | tipranks.comAtara Biotherapeutics to Cut Half of Workforce Amid RestructuringMarch 8, 2025 | marketwatch.comAtara Biotherapeutics reports Q4 EPS ($1.19) vs. ($14.00) last yearMarch 8, 2025 | markets.businessinsider.comSee More Atara Biotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Atara Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Atara Biotherapeutics and other key companies, straight to your email. Email Address About Atara BiotherapeuticsAtara Biotherapeutics (NASDAQ:ATRA) engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.View Atara Biotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Lamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go Higher Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)The Goldman Sachs Group (4/14/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
